×
About 6,825 results

ALLMedicine™ Hypercalcemia Center

Research & Reviews  1,789 results

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04933539

Jul 1st, 2022 - Background: Smoldering multiple myeloma (SMM) is a precursor condition to MM defined by the clinical parameters of M-protein >=3.0 g/dL or bone marrow plasma cells >=10%, and absence of end organ disease. Patients with high-risk SMM have a risk of...

Studies of Inherited Diseases of Metabolism
https://clinicaltrials.gov/ct2/show/NCT00001345

Jul 1st, 2022 - Familial multiple endocrine neoplasia type 1 (MEN1), familial hypocalciuric (or familial benign) hypercalcemia (FHH), hyperparathyroidism - jaw tumor syndrome (HPT-JT), other causes of familial isolated hyperparathyroidism (FIHP), and pseudohypopa...

Serum NGAL IN Patients With Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT05439538

Jun 30th, 2022 - Multiple myeloma (MM), Being one of the most common hematologic malignancies, particularly in the elderly patient, MM represents a devastating disease that occurs due to uncontrolled proliferation of a plasma cell in bone marrow , MM Presents itse...

Renal sarcoidosis.
https://doi.org/10.1007/s40620-022-01369-y 10.36141/svdld.v37i2.9142 10.3389/fimmu.2020.537382 10.1016/j.rmed.2021.106548 10.1097/MCP.0000000000000715 10.1186/s12931-018-0871-3 10.1016/S2213-2600(20)30105-3 10.1097/MCP.0000000000000504 10.1097/MCP.0000000000000800 10.1186/s12890-016-0332-z 10.1007/s00408-019-00243-2 10.1038/s41572-019-0096-x 10.1016/j.rmed.2020.106161 10.1097/MCP.0000000000000719 10.1016/j.rmed.2018.11.022 10.1097/MCP.0000000000000305 10.3389/fimmu.2020.00474 10.1038/cmi.2016.45 10.1183/13993003.00119-2019 10.1111/j.1600-065X.2008.00718.x 10.1016/j.molimm.2004.06.040 10.3390/ijms141121463 10.3390/ijms21197398 10.36141/svdld.v34i2.5369 10.2741/2692 10.1016/j.it.2020.01.007 10.1165/rcmb.2018-0053OC 10.4049/jimmunol.168.9.4620 10.1164/rccm.202002-0251ST 10.1016/S2213-2600(18)30064-X 10.1055/s-0040-1709495 10.1055/s-0040-1713615 10.12890/2021_002540 10.1097/CRD.0000000000000354 10.1016/j.cardfail.2021.06.016 10.1055/s-0040-1713130 10.23736/S2784-8671.21.07027-4 10.7759/cureus.1833 10.1016/j.autrev.2014.04.001 10.1080/25785826.2021.1940740 10.7759/cureus.10399 10.1155/2022/4657502 10.1055/s-0037-1602380 10.1186/s12931-020-1303-8 10.1177/106689690601400110 10.1097/MD.0b013e31819de50f 10.1038/ki.2010.89 10.1681/ASN.2008121226 10.1038/nri.2016.132 10.1159/000181783 10.1093/ndt/5.1.18 10.5414/cnp57142 10.1097/00007611-200406000-00016 10.1007/s10157-004-0294-y 10.1038/sj.ki.5001512 10.1053/j.ajkd.2011.09.025 10.1016/j.revmed.2012.10.009 10.1093/ckj/sfv053 10.11604/pamj.2015.22.75.6237 10.4103/1319-2442.215120 10.1136/bcr-2018-227023 10.1007/s13730-017-0287-9 10.1016/j.cca.2018.11.014 10.4103/1319-2442.292321 10.4103/1319-2442.284036 10.5414/CNP96S02 10.1159/000183258 10.1007/s13730-015-0171-4 10.1159/000046660 10.1093/ndt/18.2.280 10.2215/CJN.01790506 10.1053/j.ajkd.2016.05.004 10.1136/thoraxjnl-2021-218249 10.36141/svdld.v38i3.11488 10.1093/ndt/gft442 10.4103/1319-2442.275471 10.1097/RHU.0000000000001003 10.1007/s10157-010-0336-6 10.1159/000049044 10.1007/s13730-021-00660-4 10.15403/jgld.2014.1121.lil 10.1186/s13256-015-0764-8 10.1186/1750-1172-8-65 10.1093/ndt/gfv080 10.1093/med/9780198784081.001.0001 10.1136/thx.43.5.422 10.5414/cnp60284 10.1210/jc.2013-2016 10.1136/bcr-2015-210189 10.1210/er.2016-1070 10.1002/jbmr.2262 10.1515/jomb-2017-0041 10.1186/ar4568 10.1016/j.amjms.2016.05.027 10.1016/j.amjmed.2021.04.037 10.4103/0971-4065.116325 10.1016/j.amjmed.2021.06.023 10.1007/s11657-017-0360-1 10.1177/1078155213518361 10.1007/s13730-021-00643-5 10.1152/ajprenal.00038.2007 10.1371/journal.pone.0178872 10.1148/62.2.203 10.1136/pgmj.31.360.516 10.1016/0002-9343(56)90009-2 10.1016/s0022-5347(17)65251-0 10.1016/s0022-3476(05)80347-6 10.1093/ndt/12.10.2161 10.2147/TCRM.S83681 10.1007/s40620-019-00602-5 10.4158/ACCR-2020-0120 10.1016/j.juro.2012.11.069 10.1016/j.actbio.2018.01.040 10.1016/j.juro.2011.09.057 10.1038/nrneph.2016.101 10.1136/bcr-2013-010017 10.5414/cnp65449 10.1056/NEJM198108203050807 10.1053/sarh.2002.32548 10.1016/0002-9343(86)90828-4 10.1093/oxfordjournals.ndt.a092094 10.1016/s0272-6386(12)80961-9 10.1097/00007890-199911150-00033 10.1007/s00467-009-1137-6 10.1016/j.transproceed.2012.11.008 10.1371/journal.pone.0110778 10.1016/j.transproceed.2017.03.025 10.1007/s13730-018-0369-3 10.1055/s-0031-1298981 10.2215/CJN.03970510
Journal of Nephrology; Calatroni M, Moroni G et. al.

Jun 28th, 2022 - Sarcoidosis is a systemic inflammatory disease of unknown etiology. The pathogenesis rests on an aberrant T cell response to unidentified antigens in individuals predisposed by genetic and environmental factors. Increased expression of polarized m...

Common electrolyte abnormalities in primary care: Hypercalcemia.
https://doi.org/10.1097/01.NPR.0000843208.57823.f3
The Nurse Practitioner;

Jun 28th, 2022 - Common electrolyte abnormalities in primary care: Hypercalcemia.|2022||etiology,

see more →

Guidelines  3 results

Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494249
Journal of Clinical Oncology : Official Journal of the Am... Cook LB, Fuji S et. al.

Jan 19th, 2019 - Adult T-cell leukemia-lymphoma (ATL) is a distinct mature T-cell malignancy caused by chronic infection with human T-lymphotropic virus type 1 with diverse clinical features and prognosis. ATL remains a challenging disease as a result of its diver...

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0023
Journal of the National Comprehensive Cancer Network : JN... Kumar SK, Callander NS et. al.

Feb 12th, 2017 - Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal damage, a hallmark of multiple myeloma. Other MM-r...

SEOM guidelines on hydroelectrolytic disorders.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239780
Clinical & Translational Oncology : Official Publication ... De las Peñas R, Escobar Y et. al.

Oct 12th, 2014 - Hydroelectrolytic disorders are one of the most common metabolic complications in cancer patients. Although often metabolic alterations affecting various ions are part of the manifestations of the oncological disease, even in the form of paraneopl...

see more →

Drugs  530 results see all →

Clinicaltrials.gov  156 results

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04933539

Jul 1st, 2022 - Background: Smoldering multiple myeloma (SMM) is a precursor condition to MM defined by the clinical parameters of M-protein >=3.0 g/dL or bone marrow plasma cells >=10%, and absence of end organ disease. Patients with high-risk SMM have a risk of...

Studies of Inherited Diseases of Metabolism
https://clinicaltrials.gov/ct2/show/NCT00001345

Jul 1st, 2022 - Familial multiple endocrine neoplasia type 1 (MEN1), familial hypocalciuric (or familial benign) hypercalcemia (FHH), hyperparathyroidism - jaw tumor syndrome (HPT-JT), other causes of familial isolated hyperparathyroidism (FIHP), and pseudohypopa...

Serum NGAL IN Patients With Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT05439538

Jun 30th, 2022 - Multiple myeloma (MM), Being one of the most common hematologic malignancies, particularly in the elderly patient, MM represents a devastating disease that occurs due to uncontrolled proliferation of a plasma cell in bone marrow , MM Presents itse...

PTH Analog Type II Odontoid Fracture
https://clinicaltrials.gov/ct2/show/NCT04760782

Jun 27th, 2022 - Treatment subjects: Patients will be identified and recruited when presenting with acute fracture to our medical center. Under routine care at our center, all cervical spine fractures are evaluated, either in person or via tele-consult for remote ...

Post-Marketing Drug Intensive Monitoring Surveillance of EDIROL in Patients With Postmenopausal Osteoporosis
https://clinicaltrials.gov/ct2/show/NCT05433207

Jun 27th, 2022 - This is a post-marketing drug intensive monitoring surveillance with an observational, non-interventional design. The objectives are to compare the incidence of hypercalcemia in patients with and without calcium intake (including dietary supplemen...

see more →

News  243 results

Nab-Paclitaxel Plus Pembrolizumab Produces Promising Responses in Advanced Urothelial Cancer
https://www.onclive.com/view/nab-paclitaxel-plus-pembrolizumab-produces-promising-responses-in-advanced-urothelial-cancer

May 2nd, 2022 - The combination of nab-paclitaxel (Abraxane) and pembrolizumab (Keytruda) produced an encouraging overall response rate (ORR) with manageable safety in patients with advanced urothelial cancer who were refractory to platinum-based chemotherapy or ...

FDA Grants Orphan Drug Designation to Toripalimab for Small Cell Lung Cancer
https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-toripalimab-for-small-cell-lung-cancer

Apr 21st, 2022 - The FDA has granted an orphan drug designation to the PD-1 inhibitor toripalimab as a potential therapeutic option for patients with small cell lung cancer (SCLC), according to an announcement from Coherus BioSciences, Inc. and Shanghai Junshi Bio...

Surgery Shows No Survival, Morbidity Benefit for Mild Hyperparathyroidism
https://www.medscape.com/viewarticle/972299

Apr 18th, 2022 - Patients who receive parathyroidectomy for mild primary hyperparathyroidism show no benefits in survival or morbidity, including fractures, cancer, or cardiovascular outcomes over more than 10 years, when compared with those not receiving the surg...

Myeloma at Younger Age Shortens Lifespan Despite Lengthy Overall Survival
https://www.medpagetoday.com/hematologyoncology/myeloma/96496

Jan 4th, 2022 - Multiple myeloma at a younger age did not portend more aggressive disease or worse outcomes but significantly shortened lifespan as compared with the general population without myeloma, according to one of the largest studies of its kind. Over a 1...

Enobosarm Generates Overdue Excitement in AR+/ER+ Metastatic Breast Cancer
https://www.onclive.com/view/enobosarm-generates-overdue-excitement-in-ar-er-metastatic-breast-cancer

Dec 27th, 2021 - After decades of research, investigators are hopeful that the nonsteroidal selective androgen receptor (AR) agonist enobosarm could become an important treatment strategy following CDK4/6 inhibition in patients with AR-positive, estrogen receptor ...

see more →

Patient Education  9 results see all →